<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002739.pub3" GROUP_ID="AIRWAYS" ID="775300053015492394" MERGED_FROM="" MODIFIED="2009-01-21 11:07:51 +0100" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;M&lt;/span&gt;ariko ( 14/11/08)&lt;/p&gt;&lt;p&gt;I have revised the abstract. The numbers tally. &lt;/p&gt;&lt;p&gt;Agree that Stelmach 2008 's study is grade B for concealment of allocation. &lt;/p&gt;&lt;p&gt;Data collection paragraph has been revised. &lt;/p&gt;&lt;p&gt;Please kindly check. &lt;/p&gt;&lt;p&gt;Thanks.   &lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;TJL review 04/11/2008&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:03:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;You need to revise the abstract so that the number of studies and patients tally with what is in the review. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:16:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;I have tidied up text in the main results &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:16:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;I have deleted the unlinked figures - they were not referenced anywhere in the review. I have link&lt;/span&gt;&lt;span modified=&quot;2008-11-04 12:17:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;ed figure 1 as this is the primary outcome. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:03:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;See comments in Data collection &amp;amp; also for Stelmach 2008 in characteristics of included studies. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2008-11-04 12:02:00 +0000&quot; modified_by=&quot;Toby J Lasserson&quot; class=&quot;inserted&quot;&gt;------------------&lt;/span&gt;&lt;/p&gt;&lt;p&gt;May 22nd 2007&lt;br&gt;Hofstra data sent by Peer Reviewer but problems remain with geometric means and pooling so added to results and discussion, but not pooled. Results and discussion amended to reflect this. Signed off . CJC&lt;/p&gt;&lt;p&gt;May 16 2007&lt;br&gt;Peer Review feedback received. EIB and EIA are both used. At times the text is confusing (eg Synopsis reads as if a single dose is used 4 weeks before exercise). Data from single dose studies is misleading as it stands. Data from non placebo controlled studies could be included in the discussion (eg Subbarao).&lt;/p&gt;&lt;p&gt;CJC Editing post peer review:&lt;br&gt;I have removed this from the synopsis: &amp;quot;The use of single dose of inhaled corticosteroids taken between 15 minutes to 4 hours prior to exercise does not seem to reduce exercise induced asthma.&amp;quot;&lt;br&gt;I have revised the results in the abstract - following removed: &amp;quot;In contrast, combining results from 2 crossover studies using generic inverse variance, the use of single dose of inhaled corticosteroids of between 15 minutes to 4 hours prior to exercise did not significantly reduce the percent fall index in forced expiratory volume in 1 second (WMD= 5.04; 95% CI: -6.48 to 16.55). While the result from one study with duration of inhaled corticosteroids of 4 weeks significantly attenuated , the result from one study with single dose of inhaled corticosteroids given 15 minutes before exercise did not attenuate the percent fall in peak expiratory flow ( WMD= -7.50; 95% CI: -27.65 to 12.65).&amp;quot;&lt;br&gt;I have revised the results section in view of reservations about the design of Yazigi.&lt;br&gt;I have also removed the paragraph on protection as it currently not interpretable. These seem to be single arm results? We need to know how many were protected with placebo and how many with active treatment in each case. &amp;quot;Protection:&lt;br&gt;Two studies (Hartley 1977; Yazigi 1978) presented raw data for calculation of protection. Yazigi presented raw data for both FEV1 and PEF, therefore 2 sets of analyses were made. Protection is defined by maximum % fall index &amp;lt; 15%. Protection against fall in FEV1 was achieved in 9 out of 18 patients in Hartley's study and 3 out of 9 patients in Yazigi's study . Protection against fall in PEF was achieved in 5 out of 9 patients in Yazigi's study. Data from 2 studies could be used for calculation of clinical protection (Hartley 1977; Yazigi 1978); 1 study evaluated clinical protection as one of the outcomes (Thio 2001). Clinical protection in FEV1 was achieved in 11 out of 18 of Hartley's patients, 3 out of 9 of Yazigi's patients and 4 out of 9 of Thio's group. Clinical protection in PEF was achieved in 5 out of 9 of Yazigi's patients. &amp;quot;&lt;br&gt;Methodological limitations:&lt;br&gt;I have removed the section below because Thio did find a significant attenuation (according to the graphs). My biggest reservation is in relation to the Yazigi design, rather than the short term v long term split.&lt;br&gt;&amp;quot;In the other study which did not reveal protection against EIB by ICS (Thio 2001), the patients did not have prior ICS and there was 1 to 2 weeks of washout peroid between placebo and ICS. The similarity between the 2 studies were single dose use of ICS prior to exercise testing. Therefore the duration of treatment with ICS may have a more important role in the attenuation of EIB. Patients in the other 2 crossover studies were not on ICS prior to the study and the treatment durations lasted 4 weeks prior to exercise testing, therefore, we believe that carry-over effects were negligible.&amp;quot;&lt;br&gt;I have removed the recommendation to use parallel group studies only.&lt;br&gt;If the authors are happy with the revised version it can now be submitted.&lt;br&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;Editing by CJC April 17th&lt;/p&gt;&lt;p&gt;Authors' Contributions: fine&lt;/p&gt;&lt;p&gt;Objectives: fine&lt;/p&gt;&lt;p&gt;References:checked by Susan&lt;/p&gt;&lt;p&gt;Table of included studies: Fine. When the review is updated more details on allocation concealment and blinding will need to be added. The overall Jadad score has gone out of favour as the combined score does not mean very much.&lt;/p&gt;&lt;p&gt;Metaview Labels: I have changed the display to +/- 100 and switched off totals for comparisons where trials are included more than once 1#2 and 1#4 and #7 for example as there is currently double counting of studies. Also there seems to be inconsistent data entry for Yasgi is 1#2 subgroup 3 where SD is different from the other entries. I am also concerned that the Yasgi data is identical for 50 and 100mcg doses. Has a mistake in data entry occured here? PLEASE LOOK AT THIS AGAIN&amp;gt;&lt;br&gt;The titles of 4#2 and #3 are identical and need more detail please.&lt;br&gt;I think the labels in 6#2 need reversing and a scale of +/- 10 would be better for some of these outcomes. I have changed both.&lt;br&gt;Synopsis&lt;br&gt;See below re duration of ICS&lt;br&gt;Abstract&lt;br&gt;Please remove abbreviations from abstract. Also the disparity between durations of ICS treatment needs to be brought out in the abstract results please.&lt;br&gt;Methods&lt;br&gt;Fine&lt;br&gt;Results&lt;br&gt;Random v Fixed results is not well reported at present, I have rewritten this in red. Also there is no difference between the short and longer term study results!&lt;br&gt;&amp;quot;Clinical protection in FEV1 was achieved in 11 out of 18 of Hartley's patients, 3 out of 9 of Yazigi's patients and 4 out of 9 of Thio's group. Clinical protection in PEF was achieved in 5 out of 9 of Yazigi's patients.&amp;quot; I DO NOT UNDERSTAND THE TWO RESULTS FOR YASIGI REPORTED UNDER CLINICAL PROTECTION?&lt;br&gt;Discussion&lt;br&gt;Methodological limitations&lt;br&gt;This is my main problem with the review as it stands. The trials are very different in design in relation to duration and I think it needs to be made much clearer throughout that some studies are for several weeks duration (so this is the main question being addressed) and two are of short term duration. Conventional wisdom in asthma is that the effects of ICS increase over several weeks and I would not expect rapid loss of benefit (see below).&lt;br&gt;&amp;quot;Four studies in this review used a crossover design. The concern regarding inclusion of crossover studies in a meta-analysis are three-fold: carry-over effects, period effects and statistical issues. Data were not presented in a manner that allowed us to confirm the presence or absence of carry-over effects. However, since EIB is a short, transient condition that usually returns to baseline in one hour, and ICS is short-acting with rapid clearance from the body (Winkler 2004), we believe the carry-over effects are negligible. Were they present, it would bias the treatment effect towards the null and give it a more conservative estimate.&amp;quot;&lt;br&gt;Contentious issues&lt;br&gt;15 mins to 12 weeks is a wide range of durations!! the Yazigi design looks suspect with only very short withholding of ICS and a single treatment?&lt;/p&gt;&lt;p&gt;Next action&lt;br&gt;Back to review team to check data and also increase information about duration of treatment please. I agree with Brian that it would be much more helpful to readers if the studies of several weeks duration were kept separate from the two single dose studies, and I worry about the yazigi study with long term steroid use and a very short washout. Although it means more work to analyse the single dose treatments separately, my view is that the present version is liable to be misunderstood and does not make sense, so the other studies should NOT be combined with Thio and Yazigi&lt;/p&gt;&lt;p&gt;=====================================&lt;br&gt;BHR April 6th 2007:&lt;/p&gt;&lt;p&gt;Dear all:&lt;/p&gt;&lt;p&gt;Nice work on this review. I enjoyed reading this review. See comments below:&lt;/p&gt;&lt;p&gt;Support:&lt;br&gt;External and Internal Support? Surely someone can be acknowledged here.&lt;/p&gt;&lt;p&gt;RE: text:&lt;br&gt;Main issue is the present vs the past tense. Since the review is finished, it should be the past tense throughout.&lt;br&gt;See multiple edits in the text using the red highlight function.&lt;br&gt;Added Jadad (1996) as a &amp;#8220;Other Reference&amp;#8221; and also added a section on it.&lt;br&gt;Standardized reporting of the pooled data and 95% CI provided.&lt;br&gt;You mention Breslow-Day heterogeneity testing and then report I2 statistics. I have added the Higgins (2002) reference and a section in the text to describe the I2 statistic.&lt;br&gt;You don&amp;#8217;t need to capitalize generic drugs names. Trials evaluated a range of ICS that included budesonide &amp;#8230;.&lt;br&gt;Shouldn&amp;#8217;t start sentences with numeric values (&amp;#8220;Seven studies&amp;#8230;&amp;#8221; vs &amp;#8220;7 studies&amp;#8221;) numbers or &amp;#8220;However&amp;#8221;.&lt;br&gt;Convention is: FEV1 (subscripted &amp;#8220;1&amp;#8221;) and PEF (not PEFR).&lt;/p&gt;&lt;p&gt;My main concern is the pooling of data on EIB treated for 15 minutes with results over 6 weeks. Surely these are different and should be simply described and not pooled.&lt;/p&gt;&lt;p&gt;References:&lt;br&gt;In the text, separate the multiple references using a semi-colon (Hartley 1977; Vathenen 1991) vs (Hartley 1977, Vathenen 1991).&lt;br&gt;A few additions (Jadad and Higgins) and a few spelling mistakes identified.&lt;/p&gt;&lt;p&gt;Tables&lt;br&gt;Exclusion and inclusion tables look good.&lt;/p&gt;&lt;p&gt;Figures:&lt;br&gt;Please check the following: scaling of most figures could go up one level (to make the estimates in the figure clearer). For example, scale for the Comparison 01:02 was -10 to +10 and when switched to -100 to +100, it looks much better.&lt;/p&gt;&lt;p&gt;Acknowledgements&lt;br&gt;Any corresponding authors to thank?&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4&lt;br&gt;.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;To Paul on 30 May 2000&lt;/p&gt;" NOTES_MODIFIED="2009-01-21 09:53:31 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="CCP-AST" REVMAN_SUB_VERSION="5.0.17" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-01-21 11:07:51 +0100" MODIFIED_BY="Toby Lasserson">
<TITLE>Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction</TITLE>
<CONTACT MODIFIED="2009-01-21 11:07:51 +0100" MODIFIED_BY="Toby Lasserson"><PERSON ID="A2DE035582E26AA2011EF9F602AF3A42" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariko</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Koh</LAST_NAME><SUFFIX>MBBS, MRCP</SUFFIX><POSITION>Consultant</POSITION><EMAIL_1>kohsiyue@yahoo.com.sg</EMAIL_1><ADDRESS><DEPARTMENT>Respiratory and Critical Care Medicine</DEPARTMENT><ORGANISATION>Singapore General Hospital</ORGANISATION><ADDRESS_1>Outram Road</ADDRESS_1><CITY>Singapore</CITY><ZIP>169608</ZIP><REGION>Singapore</REGION><COUNTRY CODE="SG">Singapore</COUNTRY><PHONE_1>65-63214700</PHONE_1><FAX_1>65-62271736</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-01-21 11:07:51 +0100" MODIFIED_BY="Toby Lasserson"><PERSON ID="A2DE035582E26AA2011EF9F602AF3A42" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariko</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Koh</LAST_NAME><SUFFIX>MBBS, MRCP</SUFFIX><POSITION>Consultant</POSITION><EMAIL_1>kohsiyue@yahoo.com.sg</EMAIL_1><ADDRESS><DEPARTMENT>Respiratory and Critical Care Medicine</DEPARTMENT><ORGANISATION>Singapore General Hospital</ORGANISATION><ADDRESS_1>Outram Road</ADDRESS_1><CITY>Singapore</CITY><ZIP>169608</ZIP><REGION>Singapore</REGION><COUNTRY CODE="SG">Singapore</COUNTRY><PHONE_1>65-63214700</PHONE_1><FAX_1>65-62271736</FAX_1></ADDRESS></PERSON><PERSON ID="9DDFB8B882E26AA20078D4E6ED1052AD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Augustine</FIRST_NAME><LAST_NAME>Tee</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>augustine_tee@cgh.com.sg</EMAIL_1><EMAIL_2>augustine_tee@cgh.com.sg</EMAIL_2><URL>www.cgh.com.sg</URL><MOBILE_PHONE>(65)68503560</MOBILE_PHONE><ADDRESS><DEPARTMENT>Respiratory Medicine</DEPARTMENT><ORGANISATION>Changi General Hospital </ORGANISATION><CITY>Singapore</CITY><ZIP>529889</ZIP><COUNTRY CODE="SG">Singapore</COUNTRY><PHONE_1>(65)68503560</PHONE_1><FAX_1>(65)67816202</FAX_1></ADDRESS></PERSON><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><POSITION>Review Group Coordinator, CAG</POSITION><EMAIL_1>tlassers@sgul.ac.uk</EMAIL_1><URL>www.airways.cochrane.org</URL><ADDRESS><DEPARTMENT>Community Health Sciences</DEPARTMENT><ORGANISATION>St George's, University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><ADDRESS_2>Tooting</ADDRESS_2><CITY>London</CITY><ZIP>SW17 ORE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+20 8725 2790</PHONE_1><FAX_1>+20 8725 3584</FAX_1></ADDRESS></PERSON><PERSON ID="19605" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Louis</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Irving</LAST_NAME><SUFFIX>MBBS, FRAGP,FRACP</SUFFIX><POSITION>Director</POSITION><EMAIL_1>louis.irving@mh.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION>Royal Melbourne Hospital</ORGANISATION><ADDRESS_1>Grattan Street</ADDRESS_1><CITY>Parkville</CITY><ZIP>3050</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61-3-93427708 </PHONE_1><FAX_1>61-3-93428493 </FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-30 01:18:51 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="10" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="10" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-01-19 10:50:17 +0000" MODIFIED_BY="Toby J Lasserson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-19 10:50:17 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Literature search re-run; one new study added. Conclusions remain unchanged by the addition of new evidence.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-30 01:18:11 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="11" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-10-29 08:23:11 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2008-10-29 08:23:11 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Cochrane Airways Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-01-21 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-07-28 15:12:35 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-28 15:12:35 +0100" MODIFIED_BY="Toby J Lasserson">Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction</TITLE>
<SUMMARY_BODY>
<P>Exercise-induced asthma (bronchoconstriction) can limit a person's exercise endurance and lead to people avoiding exercise. This systematic review found that inhaled corticosteroids taken regularly can reduce exercise induced asthma in both children and adults. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-01-19 11:00:21 +0000" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>The pathogenesis of exercise induced bronchoconstriction is likely multifactorial and is not completely understood. Inflammation plays an important role in the pathogenesis of exercise induced bronchoconstriction in asthmatic subjects but the evidence seems less strong in non-asthmatic subjects. The management of exercise induced bronchoconstriction focuses on prevention, through both pharmacologic and non-pharmacologic interventions. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objectives of this review were to evaluate the use of inhaled corticosteroids in the treatment of exercise induced bronchoconstriction in a systematic way. Specifically, the review was designed to:<BR/>
</P>
<P>determine whether inhaled corticosteroids (compared to placebo) has an attenuating effect on exercise induced bronchoconstriction in adult and pediatric asthmatic patients;<BR/>estimate the magnitude of the attenuating effect.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Airways Review Group Specialised Register of trials, the Cochrane Central Register of Controlled Trials, review articles, textbooks and reference list of articles. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials in adults or children comparing inhaled corticosteroids with placebo to prevent bronchoconstriction in patients with exercise induced bronchoconstriction.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial quality assessment and data extraction were conducted independently by two reviewers.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-01-19 11:00:21 +0000" MODIFIED_BY="Toby J Lasserson">
<P>The results from eight randomised controlled trials involving 162 participants were analyzed (two trials involving adults and six involving children). Combining results from the three parallel studies with at least 4 weeks duration of inhaled corticosteroids, the use of inhaled corticosteroids significantly attenuated the percent fall index in forced expiratory volume in 1 second (WMD (fixed): 11.74%; 95% CI: 10.06% to 13.42%). The result from one crossover study with duration of inhaled corticosteroids of 4 weeks revealed significant attenuation of percent fall in forced expiratory volume in 1 second ( WMD 11.70%; 95% CI: 7.51% to 15.90%) and the percent fall in peak expiratory flow ( WMD 11.50%; 95% CI: 6.31% to 16.69%). The small amount of data from placebo-controlled trials using a single treatment do not currently allow conclusions to be drawn.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Inhaled corticosteroids used for 4 weeks or more before exercise testing significantly attenuated exercise-induced bronchoconstriction. The relative benefits of inhaled corticosteroids compared to other forms of exercise induced bronchoconstriction treatment (sodium cromoglycate, nedocromil sodium, salbutamol, and other anti-inflammatory agents) remains unclear. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-01-21 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Exercise is the most common trigger of bronchospasm and up to 90% of asthmatics have airways which are hyperactive to exercise (<LINK REF="REF-Rundell-2002" TYPE="REFERENCE">Rundell 2002</LINK>). Exercise-induced bronchoconstriction (EIB) also occurs in up to 10% of subjects who are not known to be atopic or asthmatic (<LINK REF="REF-Gotshall-2002" TYPE="REFERENCE">Gotshall 2002</LINK>). The pathogenesis of EIB is likely multifactorial and is not completely understood. Inflammation plays an important role in the pathogenesis of EIB in asthmatic subjects (<LINK REF="REF-Koh-2002" TYPE="REFERENCE">Koh 2002</LINK>; <LINK REF="REF-Otani-2004" TYPE="REFERENCE">Otani 2004</LINK>) but the evidence seems less strong in non-asthmatic subjects. </P>
<P>The management of EIB focuses on prevention, through both pharmacologic and non-pharmacologic interventions. A variety of drugs have been found useful; however, there is considerable debate regarding the merits of each agent, the optimal dose and the optimal delivery method. Traditionally, inhaled bronchodilators have been the drugs of choice. Nedocromil sodium (<LINK REF="REF-Spooner-2002" TYPE="REFERENCE">Spooner 2002</LINK>), sodium cromoglycate (<LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>) and mast cell stabilizers (<LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>) have been shown to have a statistically and clinically significant effect in attenuating EIB in three Cochrane Reviews. It is our aim to evaluate the use of inhaled corticosteroids (ICS) in the treatment of EIB in a systematic way.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-01-19 10:50:43 +0000" MODIFIED_BY="Toby J Lasserson">
<P>The objectives of this review were to evaluate the use of ICS in the treatment of EIB in a systematic way. Specifically, the review was designed to:<BR/>
</P>
<OL>
<LI>Determine whether ICS has an attenuating effect on EIB in adult and pediatric asthmatic patients;</LI>
<LI>Estimate the magnitude of the attenuating effect.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2009-01-21 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-04 11:45:39 +0000" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Any randomised, controlled trial comparing ICS with placebo. Studies with an additional treatment arm were included if the effect of ICS could be separately identified. Trials using combination inhalers ( long-acting beta agonist with inhaled corticosteroids) were not studied here. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-29 01:11:51 +0000" MODIFIED_BY="[Empty name]">
<P>All studies including children (&gt;/= 6 years) and/or adults (&gt;/= 17 years) with a history of EIB, or who demonstrate EIB in a standardised exercise challenge prior to entry into the trial, were considered for inclusion. EIB was defined as a fall in forced expiratory volume in 1 second (FEV<SUB>1</SUB>) or peak expiratory flow (PEF) following exercise of 10% or greater. Studies that did not clearly state their criteria for EIB or that included people with impairment &lt; 10% were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All patients must have been treated with an ICS or placebo as a single prophylactic treatment prior to undergoing a standardised exercise challenge test. If studies reported more than one drug arm, only the comparison of ICS drugs were included. Studies that involved delivery via nasal spray were also excluded. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-04 11:45:39 +0000" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-28 15:13:15 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The primary outcome was the maximum percent fall in pulmonary function, which is the conventional approach to quantify EIB (<LINK REF="REF-Anderson-1985" TYPE="REFERENCE">Anderson 1985</LINK>). The percent (%) fall index expresses the reduction in lung function after exercise as a percent of the pre-exercise baseline. The formula used to calculate the % fall index is: % fall FEV<SUB>1</SUB> or PEF = 100 x (pre-exercise value - lowest post-exercise value) / pre-exercise value.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-04 11:45:39 +0000" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>The proportion of participants who receive complete protection from EIB. A drug is considered to offer complete protection if the maximum % fall index is &lt; 15% (<LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>; <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>);</LI>
<LI>The number of participants who received clinical protection from EIB. As in other EIB reviews (<LINK REF="REF-Spooner-2002" TYPE="REFERENCE">Spooner 2002</LINK>; <LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>; <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>), a drug is considered to offer clinical protection if pulmonary function test (PFT) values improve by 50% or more over the placebo effect (<LINK REF="REF-ERS-1997" TYPE="REFERENCE">ERS 1997</LINK>). The formula to calculate clinical protection is: (maximum % fall placebo- maximum % fall drug)/ maximum % fall placebo x 100] (<LINK REF="REF-Anderson-1979" TYPE="REFERENCE">Anderson 1979</LINK>);</LI>
<LI>The number and nature of adverse effects experienced;</LI>
<LI>Subjective outcomes involving symptom score or performance scores;</LI>
<LI>Measurement of airway inflammation.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-01-21 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-01-21 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<P>The trials were identified using Cochrane Airways Review Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and hand searching of leading respiratory journals and meeting abstracts (please see the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/AIRWAYS/frame.html">Airways Group Module</A> for further details). All records in the Specialised Register coded as 'asthma' were searched using the following terms:</P>
<P>(exerc* OR train* OR fitness OR physical OR EIB OR EIA ) AND (corticosteroid* OR ciclesonide OR dexa* OR deca* OR fluticasone OR Flovent OR beclo* OR budesonide OR Pulmicort OR flunisolide OR Aerobid OR Bronalide OR triamcinolone OR Azmacort OR Vanceril OR Becotide OR Flixotide OR Aerobec OR Mometasone OR Qvar)</P>
<P>The most recent search was done in October 2008.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-01-21 09:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>Reference lists of all available primary studies and review articles were reviewed to identify potential relevant citations. Inquiries regarding other published or unpublished studies known and/or supported by the authors of the primary studies were made so that these results could be considered for inclusion in this review. Scientific advisors of the various pharmaceutical industries that manufacture ICS were contacted (AstraZeneca, GlaxoSmithKline, Altana) for any unpublished or interim results on ICS research involving patients with EIB. Finally, personal contact with colleagues, collaborators and other trialists working in the field of asthma were made to identify potentially relevant studies. No language or publication restrictions were applied to these searches.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-01-16 11:46:57 +0000" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-07-28 15:14:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Phase 1: Abstracts of articles identified using the above search strategy were reviewed independently by two reviewers (MK, AT) .<BR/>Phase 2: Articles that appeared to fulfill the inclusion criteria were retrieved. Using the full text of the study, two reviewers independently selected trials for inclusion in the review (MK, AT). Appropriate members of the Cochrane Airways Group screened foreign language articles and abstract data when an article qualified. All articles for which there was agreement were included; third party adjudication ( LI) was used to resolve disagreements when necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Data were extracted by two reviewers (MK, AT) and entered into the Cochrane Collaboration software program (RevMan 5.0) . All data, numeric calculations and graphic extrapolations were independently confirmed. Reviewers attempted to contact authors to identify additional papers, confirm data extraction/estimation for correctness and completeness, and to obtain missing data.</P>
<P>Data extraction included the following items:<BR/>
</P>
<UL>
<LI>Methods: study design, method of randomization, definition of EIB, exercise-testing procedure, withdrawals;</LI>
<LI>Population: recruitment, sample size, age, gender, inclusion and exclusion criteria;</LI>
<LI>Intervention: delivery device,agent, dose, timing and duration of therapy, co-intervention;</LI>
<LI>Control: agent and dose;</LI>
<LI>Outcome: PFT, protection,adverse drug reactions</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-28 15:14:51 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two reviewers ( AT, LI) assessed the methodological quality of the included trials with particular emphasis on the concealment of allocation, which was ranked using the Cochrane approach and the method of Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). One point is allocated for randomisation, blinding, and description of withdrawals and dropouts; an extra point can be added for methods of randomisation and blinding that are well-described and adequate. Studies that use a clearly inadequate method of randomisation or blinding (such as alternating patients) lose the point allocated. The maximum score is 5 points and studies scoring below 3 points are usually regarded as being of low methodological quality. Discussion or a third party adjudication will be used to resolve disagreements when necessary.</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2008-07-28 15:21:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For crossover studies mean differences were obtained for each of the included studies, and 95% CI were obtained for the difference in order to back-calculate a standard error. The P values from paired statistical tests were used to estimate a standard error, or correspondence with trialists occurred in order to obtain one.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-07-28 15:16:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For pooled effects, heterogeneity was tested using the Breslow-Day test; P &lt; 0.05 was considered statistically significant. Heterogeneity was also quantified using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Where significant heterogeneity exists, the reviewers performed sensitivity analyses based on methodological quality (high Jadad score 3-5 versus low &lt;3), and fixed vs random effect modelling.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-07-28 15:17:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Funnel plots were used to investigate the possibility of publication bias. Data from crossover studies were pooled using a random effects model of mean difference, calculated with generic inverse variance.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-01-16 11:46:57 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Trials were combined using RevMan (Version 5.0). For continuous variables, the individual statistics were reported as mean difference (MD) of treatment effect with 95% confidence interval (CI) and similar studies were pooled using weighted mean differences (WMD) using fixed effect model. For dichotomous outcome measures the individual and pooled statistics were reported as odds ratio (OR) and relative risks (RR) with 95% confidence intervals (95% CI) using fixed effect model. All similar studies were pooled using random effects OR and 95% CIs. Random effects modelling was used as sensitivity analysis. </P>
<P>The data were also evaluated for the presence of publication bias using graphical and statistical methods.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-28 15:17:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<I>A-priori</I>, heterogeneity was examined using the following subgroups:<BR/>
</P>
<UL>
<LI>Age of patients (less than or greater than 16 years);</LI>
<LI>Duration of treatment with ICS (less than or more than 2 weeks)</LI>
<LI>Dose of ICS used in the study (steroid naive, less than or greater than 400 mcg equivalent of beclomethasone dipropionate);</LI>
<LI>Severity of asthma (degree of EIB before entry into the study, mean Maximum % fall in FEV1 or PEF &lt;30% is mild and more than or greater than 30% is moderate-severe) <LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>, <LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>);</LI>
<LI>Atopic asthma versus non-atopic asthma;</LI>
<LI>Different delivery devices used.</LI>
</UL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-01-19 10:51:50 +0000" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2009-01-19 10:51:08 +0000" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Using the search strategy described above, 193 titles and abstracts were selected from the computerised databases. From the text in the title, abstract and keywords, two authors independently selected 30 studies for full text review. The two independent reviewers subsequently determined that eight trials met inclusion criteria (100% agreement ). Review of reference lists did not yield any additional trials for inclusion.</P>
<P>Summary details are given in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, and described in general terms below.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-01-19 10:51:08 +0000" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="6">Design issues</HEADING>
<P>Four studies used a parallel group design and four used crossover designs. All eight trials except for one (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>) were double-blind studies. In the cross-over studies, wash-out periods ranged between 24 hours (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>) to 2 weeks (<LINK REF="STD-Thio-2001" TYPE="STUDY">Thio 2001</LINK>). One study did not mention duration of washout (<LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Population</HEADING>
<P>Studies included children and adults (age range: 4-45 years). While eight trials were identified for inclusion, results from one study (<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>) were presented in geometric mean and attempts in contacting the authors for raw data were unsuccessful. Consequently, the meta-analysis was performed using results from seven trials with 172 participants (94 males, 39 females, 39 not stated). Two trials involved adults (<LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>; <LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK>) and the other five trials involved children. There were 75 adults between the ages of 17-45 years and 97 children between the ages of 6-16 years. There were 10 drop-outs altogether and analysis was performed using results from 162 patients: 113 patients were in the ICS arm and 110 patients in the placebo arm. Three studies included only stable asthmatics, otherwise stability of asthma was not mentioned. Recruitment procedures were not well described in most studies. Concomitant therapy included a variety of medications and most commonly included short acting beta agonists, which were discontinued for at least 6 hours before the exercise test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Interventions</HEADING>
<P>Trials evaluated a range of ICS that included budesonide (N=4) between 50 to 200 mcg/day, fluticasone (N=2) between 200 to 1000 mcg/day, betamethasone (N=1) at 800 mcg/day and triamcinolone (N=1) at 300 mcg per day. There was a wide range of treatment duration between the studies. Patients in two studies were given single dose of ICS 15 minutes and 4 hours prior to exercise testing (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>; <LINK REF="STD-Thio-2001" TYPE="STUDY">Thio 2001</LINK>). The other six studies had duration of ICS ranging between 4 to 12 weeks before a standardised exercise challenge test. All studies except for one (<LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>) used treadmill as the exercise challenge. <LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK> utilised cycle ergometer as a form of exercise challenge test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcomes</HEADING>
<P>Seven studies measured maximum fall in FEV<SUB>1 </SUB>after exercise. One study (<LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>) measured fall in PEF after exercise and another (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>) measured both PEF and FEV<SUB>1</SUB> after exercise. In addition, 1 study ( <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>) reported PD 20 methacholine and serum eosinophil cationic protein levels, 3 studies measured symptom score ( <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>; <LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>), 1 study ( <LINK REF="STD-Petersen-2004" TYPE="STUDY">Petersen 2004</LINK>) measured exhaled nitric oxide levels and 1 study (<LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK>) measured FEV<SUB>1</SUB> response to histamine (PD 20 histamine) and Eucapnic Voluntary Hyperventilation (EVH) response. One study reported area under curve for FEV<SUB>1</SUB>values from exercise over 20-minute period <U>(</U>
<LINK REF="STD-Stelmach-2008" TYPE="STUDY">Stelmach 2008</LINK>
<U>)</U>. Two studies monitored adverse events (<LINK REF="STD-Petersen-2004" TYPE="STUDY">Petersen 2004</LINK>; <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-07-28 15:19:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-01-16 11:47:43 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Using the Cochrane criteria to assess allocation concealment, all the studies were given "unclear" status. Using Jadad's 5 point validity scale, 1 study was rated 4 (very good), 6 studies were rated 3 (good) and one study was rated 2 (poor). All studies except for one lacked sufficient description of the method of randomisation and blinding used.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-01-19 10:51:50 +0000" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="6">Pulmonary function</HEADING>
<P>Although all eight trials fulfilled the criteria for inclusion, results from one study could not be used for meta-analysis (<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>). As such, the meta-analysis was conducted using data from 7 studies with 162 participants completing the studies.</P>
<P>Combining results from three parallel studies (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>; <LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK>
; <LINK REF="STD-Stelmach-2008" TYPE="STUDY">Stelmach 2008</LINK>), the use of ICS given for a duration of 4 to 12 weeks significantly attenuated the % fall index in FEV<SUB>1</SUB> (WMD (fixed): 11.74%; 95% CI: 10.06% to 13.42%; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>); the results demonstrated a large degree of heterogeneity (I<SUP>2</SUP> 81%). Sensitivity analysis based on a random effects model yielded slightly wider confidence intervals (11.70%; 95% CI: 7.51% to 15.90%). There are several differences in the three study designs. <LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK> included steroid-naive children with EIB (aged between 7-16 years) who received low dose budesonide of 100 mcg bd (via turbohaler inhaler) or placebo inhaler for 12 weeks. <LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK> included adult patients (aged 18-45 years) who were positive on bronchoprovocation test (histamine) and EVH test and most of the patients were atopic (37 out of 40) based on positive skin prick to at least one allergen. The treatment arm patients were given higher doses of budesonide (800 mcg bd) via metered dose inhaler (MDI) with spacer and the effects were studied after 6 weeks. <LINK REF="STD-Stelmach-2008" TYPE="STUDY">Stelmach 2008</LINK> included children (aged 6 to 18 years) who were on inhaled budesonide (average of 400 mcg/day) and montelukast or long-acting bronchodilator for at least 6 months prior to the study. In addition, they were all atopic, as defined by positive skin prick tests to house dust mites. The treatment arm received Inhaled budesonide (100 mcg bid) for 4 weeks. Therefore, the study designs differed in the population studied, type, duration and dose of corticosteroid used. Possibility of publication bias could not be assessed using funnel plot with such a low number of studies.</P>
<P>
<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK> was in children aged six to fourteen years who had used no inhaled steroids in the previous 4 months. As the data for lung function were not normally distributed natural log-transformation was applied and geometric means were reported. Compared to placebo both 100 mcg and 250 mcg Fluticasone twice daily significantly attenuated the % fall in FEV<SUB>1</SUB> with exercise when measured at three and six weeks (P&lt; 0.05). The magnitude of this difference (around 17%) was in keeping with the results of <LINK REF="STD-Jonasson-2000" TYPE="STUDY">Jonasson 2000</LINK> and <LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK>.</P>
<P>Data from crossover studies were pooled using a Random effects MD calculated with generic inverse variance. The result from one crossover study with duration of inhaled corticosteroids of 4 weeks revealed significant attenuation of % fall in FEV1 for both doses of budesonide (100 mcg/day and 50 mcg/day), (MD 6.90%; 95% CI: 1.40% to 12.40% and WMD 7.00%; 95% CI: 0.15% to 13.85% respectively, <LINK REF="STD-Petersen-2004" TYPE="STUDY">Petersen 2004</LINK>). Similarly the result from one study with duration of inhaled corticosteroids of 4 weeks significantly attenuated the % fall in PEF (MD 11.50%; 95% CI: 6.31% to 16.69%, <LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>).</P>
<P>Combining results from 2 crossover studies with single dose of ICS use between 15 minutes to 4 hours prior to exercise (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>; <LINK REF="STD-Thio-2001" TYPE="STUDY">Thio 2001</LINK>), the use of ICS did not significantly reduce the % fall index in FEV<SUB>1</SUB> (MD 5.04%; 95% CI: -6.48% to 16.55%); a moderate level of heterogeneity was present, (I <SUP>2 </SUP>= 41.9%). The result from one study (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>) with inhaled corticosteroids given 15 minutes before exercise did not significantly attenuate the % fall in PEF ( WMD= -7.50; 95% CI: -27.65 to 12.65 ). <LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK> included asthmatic children (aged 8-15 years) who had already been receiving treatment with triamcinolone acetonide aerosol (100 mcg od -300 mcg qid) for control of severe asthma. Medications were only withheld for 12 hours before a single dose of either triamcinolone (300 mcg) or placebo inhalers were administered and this was separated by a washout period of 24 hours for the crossover study. In contrast, <LINK REF="STD-Thio-2001" TYPE="STUDY">Thio 2001</LINK> included patients that were steroid-naive for 3 months prior to the study and had wash-out periods of 7 -14 days, and the study patients were given fluticasone 1 mg 4 hours prior to exercise. Regular previous use of inhaled corticosteroids may have attenuated the results of treatment in <LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>. Due to small number of studies and sample sizes, firm conclusions about the effect of single dose treatments cannot be made.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Side effects</HEADING>
<P>There were no significant differences in adverse event reported between the group with beclomethasone 100 mcg/day and placebo in Petersen's group (OR 1.40; 95% CI: 0.28 to 7.00). There were also no significant differences in adverse event reported between the group with beclomethasone 50 mcg/day and placebo (OR 0.31; 95% CI: 0.03 to 3.16). In another study (<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>), the authors stated that no clinically significant abnormalities in heart rate and blood pressure were observed and most adverse events were related to respiratory infections, or contacts with allergen; however, no data were presented.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptom score</HEADING>
<P>One study (<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>) failed to present any raw data on symptom score except to mention that there appeared significantly more days and nights without wheeze when using active treatment (fluticasone) compared to placebo (P&lt;0.05). No effect of fluticasone was found on symptom scores of cough, shortness of breath and exercise-induced symptoms. In another study (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>), a significant reduction in symptom scores during daytime was found in the treatment group compared with placebo (MD = 0.43; 95% CI 0.2 to 0.7). Finally, one study (<LINK REF="STD-Hartley-1977" TYPE="STUDY">Hartley 1977</LINK>) reported mean symptom score did not differ significantly between ICS and placebo (paired t-test , P&gt;0.05). Due to the lack of information regarding the symptom score measurement and method of measurement, pooled analyses were not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Airway inflammation</HEADING>
<P>One study (<LINK REF="STD-Vathenen-1991" TYPE="STUDY">Vathenen 1991</LINK>) reported the dose of histamine causing 20% fall in FEV<SUB>1</SUB> (PD 20) in the group between those who received ICS and those who received placebo. There were no significant differences between the PD20 in both groups (P=0.28). Another study (<LINK REF="STD-Petersen-2004" TYPE="STUDY">Petersen 2004</LINK>) reported the mean exhaled nitric oxide (eNO) between budesonide and placebo. They found significantly lower mean eNO levels in the ICS groups (both budesonide 50 mcg/day and budesonide 100 mcg/day) compared to placebo (WMD = 5.39; 95% CI: 5.00 to 5.78). There were no differences in mean eNO levels between the 2 doses of budesonide. Although serum levels of eosinophilic cationic protein (sECP) were reported in one study (<LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK>) for active treatment and placebo, results were presented in geometric mean and raw data was unavailable. The authors mentioned in their paper that sECP levels did not change significantly during treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>
<I>A priori</I> sub-group comparisons based on age, dose of study medication, severity of asthma, atopic status and delivery devices would be tested for heterogeneity, but due to the small number of trials, we could not perform any sub-group analysis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-04 11:47:28 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Exercise-induced bronchoconstriction (EIB) is a significant clinical problem for which effective and safe prophylactic treatment is necessary. This systematic review and meta-analysis of seven randomised controlled trials in 172 patients seems to suggest there are protective effects of ICS against EIB when ICS were given for 4 weeks or more prior to the exercise testing. The small amount of data from 2 studies using single doses of ICS, given 15 minutes and 4 hours prior to exercise testing, do not allow any firm conclusions to be drawn.</P>
<P>The speed of onset of protection and the dose response are currently uncertain. <LINK REF="STD-Hofstra-2000" TYPE="STUDY">Hofstra 2000</LINK> found benefit in children at three weeks and six weeks on both 100 mcg and 250 mcg twice daily. A recent study (<LINK REF="STD-Subbarao-2006" TYPE="STUDY">Subbarao 2006</LINK>) compared 4 doses of Ciclesonide to prevent EIB over a four week period, and an attenuation in EIB was found starting after one week of treatment in all but the lowest dose treatment arm (40 micrograms per day) when compared to baseline. The effect seemed to increase over 4 weeks in the higher dose arm (320 micrograms per day). There was no placebo arm in this study and there were no significant differences between the arms of the study, nor between the results at different time points, but the numbers were small. Nevertheless this study gives some useful pointers to the speed of onset of inhaled corticosteroids in the prevention of EIB, which may show benefit as early as one week, but may not reach a plateau until much later. Both the speed of onset and dose response need further research on larger numbers of adults and children.</P>
<P>The protective effects of inhaled corticosteroids ranged between 33% to 56% and clinical protection was demonstrated from 3 studies to be between 33% to 61%. The rate of adverse events between ICS and placebo was not significant from one study which reported this outcome. Due to the lack of information regarding symptom measurements, pooling the data for analysis was not possible. Data also could not be combined for analysis due to differences in measurement of airway inflammation.</P>
<SUBSECTION>
<HEADING LEVEL="6">Methodological limitations</HEADING>
<P>The authors have identified several potential methodological limitations in this review.<BR/>
</P>
<OL>
<LI>Publication and selection biases. A comprehensive search of published literature for potentially relevant studies was conducted, and attempts were made to contact corresponding and first authors to identify unpublished data due to the possibility of missed unpublished negative trials. Abstracts from meetings were also reviewed for potential inclusion and none were found to fulfill the inclusion criteria. Though it is possible that selection bias occurred, we employed two independent reviewers for the selection process and we are confident that the studies excluded were done so for appropriate reasons and in a consistent manner.</LI>
<LI>The overall small number of studies and sample sizes introduces a note of caution. Ideally, more RCTs should be conducted to verify the results in the future.</LI>
<LI>Four studies in this review used a crossover design. The concern regarding inclusion of crossover studies in a meta-analysis are three-fold: carry-over effects, period effects and statistical issues. Data were not presented in a manner that allowed us to confirm the presence or absence of carry-over effects. Although EIB is a short, transient condition that usually returns to baseline in one hour, and ICS is short-acting with rapid clearance from the body (<LINK REF="REF-Winkler-2004" TYPE="REFERENCE">Winkler 2004</LINK>), one of the studies included patients with severe asthmatics on long-term inhaled corticosteroids for which the inhaled corticosteroid was withheld for only 12 hours before the exercise testing (<LINK REF="STD-Yazigi-1978" TYPE="STUDY">Yazigi 1978</LINK>) . Therefore carry-over effects could be present which may account for the lack of protection of ICS against EIB in this study.</LI>
<LI>Period effect comes into play since EIB is a variable condition and it is possible that baseline PFT values could vary prior to each exercise challenge. Individuals could randomly experience a change in baseline airflow values depending on many of the factors (humidity, temperature). Had there been a period effect in every study, there would be no reason to believe any systematic bias towards any one period. By averaging the estimates, the period effect would disappear leaving an unbiased estimate of the treatment contrast (<LINK REF="REF-Senn-1991" TYPE="REFERENCE">Senn 1991</LINK>).</LI>
<LI>Details regarding acceptable randomisation, allocation concealment and blinded outcomes assessment were not adequately reported in all the studies.</LI>
</OL>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-04 11:47:22 +0000" MODIFIED_BY="Toby J Lasserson">
<IMPLICATIONS_PRACTICE>
<P>Inhaled corticosteroids given for 4 weeks or more are effective in preventing deterioration in lung function post-exercise in both adults and children. There is currently insufficient evidence to draw conclusions about shorter durations of treatment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-04 11:47:22 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Further research should focus on:<BR/>
</P>
<OL>
<LI>Comparing ICS in patients with EIB with different doses of inhaled corticosteroids over a range of durations, more severe EIB ( % fall FEV1 or PEFR &gt; 30%), atopic and non-atopic asthmatics, and different types of delivery devices.</LI>
<LI>The effects of ICS should be assessed in eucapnic voluntary hyperventilation (EVH) test -proven EIB. EVH is the current challenge test recommended by the International Olympic Committee as the optimal laboratory based challenge test for the identification of EIB.</LI>
<LI>Improving reporting of recruitment procedures, methodology and effect estimates accompanied by variance estimates for all outcomes.</LI>
<LI>Correlating physiological benefits with other outcomes such as symptoms scores, athletic or exercise performance and patient preference.</LI>
<LI>Comparing ICS to other drugs or in combination with other drugs.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-29 09:16:11 +0000" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank the support staff of the Cochrane Airways Group especially Mr Toby Lasserson and Ms Elizabeth Arnold who have provided invaluable assistance in terms of statistical support and assistance in the electronic search and retrieval of papers. Professor Brian Rowe was the assigned editor for this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-10-29 09:16:23 +0000" MODIFIED_BY="[Empty name]">
<P>Koh MS: reviewed abstracts for inclusion; data extraction; discussion.<BR/>Tee A: reviewed abstracts for inclusion; data extraction; assessed methodological quality of trials.<BR/>Irving L: assessed methodological quality of trials.<BR/>Lasserson T: provided advice on data extraction, entry and analysis for GIV outcomes.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This protocol has been withdrawn as it is out of date and will be re-allocated to a new review author team.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-01-21 09:53:31 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-01-21 09:53:31 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-01-21 09:52:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hartley-1977" NAME="Hartley 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartley JPR, Charles TJ, Seaton A</AU>
<TI>Bethamethasone valerate inhalation and exercise -induced asthma in adults</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1977</YR>
<VL>71</VL>
<NO>4</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstra-2000" MODIFIED="2009-01-21 09:52:44 +0000" MODIFIED_BY="[Empty name]" NAME="Hofstra 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-21 09:52:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PGH, Kuethe MC et al</AU>
<TI>Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine -induced bronchoconstriction in children with asthma</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>6</NO>
<PG>415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonasson-2000" MODIFIED="2009-01-21 09:46:24 +0000" MODIFIED_BY="[Empty name]" NAME="Jonasson 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-21 09:46:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen KH, Hultquist C</AU>
<TI>Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren</TI>
<SO>Pediatric Allergy &amp; Immunology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>2</NO>
<PG>120-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-2004" MODIFIED="2009-01-21 09:46:44 +0000" MODIFIED_BY="[Empty name]" NAME="Petersen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-21 09:46:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen R, Agertoft L, Pedersen S</AU>
<TI>Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>932-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stelmach-2008" MODIFIED="2009-01-16 11:49:13 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Stelmach 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-16 11:49:13 +0000" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P</AU>
<TI>Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>383-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-29 07:43:59 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thio-2001" MODIFIED="2009-01-21 09:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="Thio 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-21 09:52:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thio BJ, Slingerland GLM, Nagelkerke AF, Roord JJ, Mulder PGH, Dankert-Roelse JE</AU>
<TI>Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: A pilot study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>2</NO>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vathenen-1991" MODIFIED="2009-01-21 09:46:54 +0000" MODIFIED_BY="[Empty name]" NAME="Vathenen 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-01-21 09:46:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE</AU>
<TI>Effect of inhaled budesonide on bronchial reactivity to histamine, exercise , and eucapnic dry air hyperventilation in patients with asthma</TI>
<SO>Thorax</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>11</NO>
<PG>811-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yazigi-1978" NAME="Yazigi 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yazigi R, Sly RM, Frazer M</AU>
<TI>Effect of traimcinolone acetonide aerosol upon exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1978</YR>
<VL>40</VL>
<NO>5</NO>
<PG>322-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-01-21 09:53:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Beck_x002d_Ripp-2002" MODIFIED="2009-01-21 09:47:15 +0000" MODIFIED_BY="[Empty name]" NAME="Beck-Ripp 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-21 09:47:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck-Ripp J, Griese M, Arenz S, Koring C, Pasqualoni B, Bufler P</AU>
<TI>Changes of exhaled nitric oxide during steroid treatment of childhood asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1015-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duong-2008" MODIFIED="2009-01-21 09:47:21 +0000" MODIFIED_BY="[Empty name]" NAME="Duong 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-21 09:47:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Duong
 M, Subbarao P, Adelroth E, Obminski G, Strinich T, Inman M, Pedersen S, O'Byrne PM
</AU>
<TI>
Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma
</TI>
<SO>
Chest 
</SO>
<YR>
2008
</YR>
<VL>
133
</VL>
<PG>
404-1
</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freezer-1995" NAME="Freezer 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freezer NJ, Croasdell H, Doull IJM, Holgate ST</AU>
<TI>Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in schoolchildren with recurrent wheeze</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>9</NO>
<PG>1488-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksen-1983" NAME="Henriksen 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM, Dahl R</AU>
<TI>Effects of inhaled budesonide alone and comination with low-dose terbutaline in children with exercise-induced asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1983</YR>
<VL>128</VL>
<NO>6</NO>
<PG>993-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksen-1985" NAME="Henriksen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM</AU>
<TI>Effect of inhalation of corticosteroids on exercise induced asthma: randomised double blind crossover study of budesonide in asthmatic children</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>291</VL>
<NO>6490</NO>
<PG>248-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hodges-2005" MODIFIED="2009-01-21 09:47:32 +0000" MODIFIED_BY="[Empty name]" NAME="Hodges 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-21 09:47:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hodges ANH, Lynn BM, Koehle MS, McKenzie DC</AU>
<TI>Effects of inhaled bronchodilators and corticosteroids on exercise induced arterial hypoxaemia in trained male athletes</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>12</NO>
<PG>917-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonasson-1998" NAME="Jonasson 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen KH, Blomqvist P</AU>
<TI>Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>5</NO>
<PG>1099-1104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonasson-2000a" MODIFIED="2009-01-21 09:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Jonasson 2000a" YEAR="2000">
<REFERENCE MODIFIED="2009-01-21 09:47:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen KH, Jonasson C, Mowinckel P</AU>
<TI>Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>8</NO>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1974" MODIFIED="2009-01-21 09:47:55 +0000" MODIFIED_BY="[Empty name]" NAME="Konig 1974" YEAR="1974">
<REFERENCE MODIFIED="2009-01-21 09:47:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Jaffe P, Godfrey S</AU>
<TI>Effect of corticosteroids on exercise-induced asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1974</YR>
<VL>54</VL>
<NO>1</NO>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molema-1989" MODIFIED="2009-01-21 09:48:02 +0000" MODIFIED_BY="[Empty name]" NAME="Molema 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-21 09:48:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molema J, van Herwaarden CLA, Folgering HTM</AU>
<TI>Effects of inhaled budesonide on the relationships between symptoms, lung function indices and airway hyperresponsiveness in patients with allergic asthma</TI>
<SO>Pulmonary Pharmacology</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>4</NO>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molema-1989a" MODIFIED="2009-01-21 09:48:08 +0000" MODIFIED_BY="[Empty name]" NAME="Molema 1989a" YEAR="1989">
<REFERENCE MODIFIED="2009-01-21 09:48:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molema J, van Herwaarden CLA, Folgering HTM</AU>
<TI>Effects of long-term teatment with inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with allergic asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>4</NO>
<PG>308-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morice-2008" MODIFIED="2008-10-29 08:12:08 +0000" MODIFIED_BY="[Empty name]" NAME="Morice 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-10-29 08:12:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Morice AH, Peterson S, Beckman O, Ku
kova Z
</AU>
<TI>
Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: A superiority and therape
u
tic equivalence study
</TI>
<SO>
Pulmonary Pharmacology and Therapeutics
</SO>
<YR>
2008
</YR>
<VL>
21
</VL>
<PG>
152-9
</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nankani-1990" MODIFIED="2009-01-21 09:48:15 +0000" MODIFIED_BY="[Empty name]" NAME="Nankani 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-01-21 09:48:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nankani JN, Northfield M, Beran YM, Richardson PD</AU>
<TI>Changes in asthmatic patients' symptoms and lifestyles on institution of inhaled budesonide therapy</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>3</NO>
<PG>198-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-2003" MODIFIED="2009-01-21 09:48:23 +0000" MODIFIED_BY="[Empty name]" NAME="Nathan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-21 09:48:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Dorinsky P, Rosenzweig JRC, Shah T, Edin H, Prillaman B</AU>
<TI>Improved ability to perform strenuous activities after treatment with fluticasone Priopionate/Salmeterol combination in patients with persistent asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2003</YR>
<VL>40</VL>
<NO>7</NO>
<PG>815-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patakas-1978" NAME="Patakas 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patakas D, Louridas G, Sehletidis L</AU>
<TI>Effect of beclomethasone dipropionate inhalation on exercise induced bronchospasm</TI>
<SO>IRCS Medical Science. Cardiovascular System</SO>
<YR>1978</YR>
<VL>6</VL>
<NO>11</NO>
<PG>448</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1995" NAME="Pedersen 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen S, Hansen OR</AU>
<TI>Budesonide treatment of moderate and severe asthma in children: A dose-response study</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1995</YR>
<VL>95</VL>
<NO>1 Pt 1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Per-Venge-1991" NAME="Per Venge 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venge P, Henriksen J, Dahl R</AU>
<TI>Eosinophils in exercise-induced asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1991</YR>
<VL>88</VL>
<NO>5</NO>
<PG>699-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichaipat-1995" MODIFIED="2009-01-21 09:53:31 +0000" MODIFIED_BY="[Empty name]" NAME="Pichaipat 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-21 09:53:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichaipat V, Tongpenyai Y, Nerntong T, Sriprapachiranont C</AU>
<TI>The protective effect of inhaled terbutaline, sodium cromogylcate and budesonide on exercise-induced asthma in children</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1995</YR>
<VL>78</VL>
<NO>10</NO>
<PG>505-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subbarao-2006" NAME="Subbarao 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subbarao P, Duong M, Adelroth E, Otis J, Obminski G, Inman M et al</AU>
<TI>Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>5</NO>
<PG>1008-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vidal-2001" MODIFIED="2009-01-21 09:48:40 +0000" MODIFIED_BY="[Empty name]" NAME="Vidal 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-21 09:48:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vidal C, Fernandez-Ovide E, PineiroJ, Nunez R, Gonzalez-Quintela A</AU>
<TI>Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction</TI>
<SO>Annals of Allergy, Asthma, &amp; Immunology</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>6</NO>
<PG>655-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waalkens-1993" NAME="Waalkens 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waalkens HJ, van Essen-Zandvliet EEM, Gerritsen J, Duiverman EJ, Kerrebjin KF, Knol K</AU>
<TI>The effect of an inhaled corticosteroid ( budesonide) on exercise-induced asthma in children</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>5</NO>
<PG>652-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-2005" MODIFIED="2009-01-21 09:48:48 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-21 09:48:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AM, Duong M, Pratt B, Dolovich M, O'Byrne PM</AU>
<TI>Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<NO>5</NO>
<PG>537-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-01-21 09:49:18 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-01-21 09:49:18 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anderson-1979" MODIFIED="2009-01-21 09:49:03 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1979" TYPE="JOURNAL_ARTICLE">
<AU>Anderson S, Seale JP, Ferris L, Schoeffel R, Lindsay DA</AU>
<TI>An evaluation of pharmacotherapy for exercise-induced asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1979</YR>
<VL>64</VL>
<NO>6 pt 2</NO>
<PG>612-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1985" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anderson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD</AU>
<TI>Issues in exercise-induced asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1985</YR>
<VL>76</VL>
<NO>6</NO>
<PG>763-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ERS-1997" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ERS 1997" TYPE="JOURNAL_ARTICLE">
<AU>European Respiratory Society Task Force</AU>
<TI>Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>11</NO>
<PG>2662-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gotshall-2002" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Gotshall 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gotshall RW</AU>
<TI>Exercise-induced bronchoconstriction</TI>
<SO>Drugs</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>12</NO>
<PG>1725-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2009-01-21 09:49:18 +0000" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2000" MODIFIED="2009-01-19 10:54:53 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Kelly 2000" TYPE="COCHRANE_REVIEW">
<AU>Kelly K, Spooner CH, Rowe BH</AU>
<TI>Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-01-19 10:54:45 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2009-01-19 10:54:45 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD002731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koh-2002" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Koh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Koh YI, Choi S</AU>
<TI>Blood eosinophil counts for the prediction of the severity of exercise-induced bronchospasm in asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>2002</YR>
<VL>96</VL>
<NO>2</NO>
<PG>120-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Otani-2004" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Otani 2004" TYPE="JOURNAL_ARTICLE">
<AU>Otani K, Kanazawa H, Fujiwara H, Hirata K, Fujimoto S, Yoshikawa J</AU>
<TI>Determinants of the severity of exercise-induced bronchoconstriction in patients with asthma</TI>
<SO>Journal of Asthma</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>3</NO>
<PG>271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rundell-2002" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rundell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rundell KW, Jenkinson DM</AU>
<TI>Exercise-induced bronchospasm in the elite athlete</TI>
<SO>Sports Medicine</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>9</NO>
<PG>583-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senn-1991" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Senn 1991" TYPE="JOURNAL_ARTICLE">
<AU>Senn SJ, Hildebrand H</AU>
<TI>Crossover trials, degress of freedom, the carryover problem and its dual</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1361-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spooner-2002" MODIFIED="2009-01-19 10:57:16 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Spooner 2002" TYPE="COCHRANE_REVIEW">
<AU>Spooner CH, Saunders LD, Rowe BH</AU>
<TI>Nedocromil sodium for preventing exercise-induced bronchoconstriction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-01-19 10:57:16 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2009-01-19 10:57:16 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD001183"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Spooner-2003" MODIFIED="2009-01-19 10:57:54 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Spooner 2003" TYPE="COCHRANE_REVIEW">
<AU>Spooner CH, Spooner GR, Rowe BH</AU>
<TI>Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-01-19 10:57:54 +0000" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2009-01-19 10:57:54 +0000" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD002307"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Winkler-2004" MODIFIED="2008-07-28 15:21:00 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Winkler 2004" TYPE="JOURNAL_ARTICLE">
<AU>Winkler J, Hocchaus G, Derendorf H</AU>
<TI>How the lung handles drugs. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids</TI>
<SO>Proceedings of the American Thoracic Society</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>4</NO>
<PG>356-363</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-01-19 10:52:20 +0000" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-01-19 10:52:20 +0000" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Hartley-1977">
<CHAR_METHODS>
<P>RCT, double-blind, crossover study<BR/>No withdrawal or drop-out<BR/>Concomitant treatment: bronchodilators allowed( except &lt; 12 hours of exercise test)<BR/>Exclusion: no prior corticosteroids or cromoglycate <BR/>Exercise test: cycle ergometer, 9 min to oxygen uptake of 65-90mmol/min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=18. 12m, 6f. Age 17-40 years, mean 29 years. 14 had positive skin prick test to common allergens. All had EIB as defined by fall in peak expiratory flow rate (PEFR) of at least 15% after exercise.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: betamethasone valerate inhaler 200 mcg QDS for 4 weeks or placebo inhaler in identical container</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF immediately, and at 5 min interval for 20 min. The lowest value was taken as indicating PEFR after exercise(a) and this figure compared with PEFR before exercise(b)&gt; Percentage fall index was then calculated. Ratio of a/b and its logarithmic form were also analysed. The difference in PEFR fall after bethamethasone and placebo were compared by a paired sample t-test on log of a/b. Adverse events were not mentioned.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jada score =3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hofstra-2000">
<CHAR_METHODS>
<P>RCT, double-blind, parallel study<BR/>1 drop-out due to non-compliance<BR/>Concomitant treatment: intranasal and topical steroids, eye cromones, inhaled cromoglycate ( stopped at screening visit)<BR/>exercise test: treadmill to achieve heart rate of &gt;90% predicted.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 37. 23m,14f. mean age 10.3 years. 32 patients were atopic to at least one inhalant allergen on RAST test. All had fall in FEV1 of at least 20% post exercise.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: fluticasone propionate 100 mcg bid or fluticasone propionate 250mcg bid or placebo using MDI attached to volumetric spacer for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, % fall after exercise, PD20 methacholine, serum eosinophil cationic protein and symptom scores were measured. Adverse events were monitored.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score =3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-28 15:23:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Jonasson-2000">
<CHAR_METHODS MODIFIED="2008-07-28 15:23:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>RCT, parallel<BR/>Concomitant treatment: terbutaline turbohaler as needed<BR/>Exercise test: treadmill to achieve heart rate of 170-180/min.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 28.22m,6 f. Mean age 9.7 years. All had EIB as defined by reduction in FEV1 of at least 10 % after exercise.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: budesonide turbohaler 100 mcg bid or placebo for 12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean maximum fall in FEV1 after exercise , symptom score and use of rescue medications were measured.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score=2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-28 15:23:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Petersen-2004">
<CHAR_METHODS MODIFIED="2008-07-28 15:23:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>RCT, crossover, double blind study<BR/>2 -week run-in period, followed by three 4-week study periods , each separated by a 1-week washout. The following treatments were given during the double-blind periods: budesonide 50 mcg, budesonide 100 mcg and placebo.<BR/>2 drop-outs due to asthma exacerbation and toe fracture<BR/>Concomitant treatment: short acting beta agonist as needed<BR/>Exercise test: treadmill to achieve heart rate of &gt; 180/min</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=27. 20m, 7 f. Age 6-14 years, mean age 10.6. All had FEV1 &gt; 70% predicted and post exercise reduction in FEV1 of at least 15%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: Budesonide autohaler 50 mcg or 100 mcg or placebo for 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-28 15:23:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Maximal percentage fall in FEV1 after exercise was measured. The percentage fall from pre-exercise at each time point was also calculated. The mean percentage fall in FEV1 was plotted against time for each treatment. The area under the curve (AUC) for the percentage fall in FEV1 from exercise over the 20 min period was calculated using trapezoidal rule. In addition, exhaled nitric oxide measurements were made from the start of the run-in and at the end of study period. Adverse events were recorded.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-19 10:52:20 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Stelmach-2008">
<CHAR_METHODS MODIFIED="2008-10-29 08:56:54 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, double-blind, parallel study.</P>
<P>Regular medications stopped for 4 weeks. </P>
<P>Concomitant treatment: bronchodilators allowed ( except &lt; 6 hours of exercise test).</P>
<P>Exercise test: treadmill to achieve heart rate of 95% maximum predicted for age.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-19 10:52:20 +0000" MODIFIED_BY="Toby J Lasserson">
<P>N= 39. Age 6-18 years. Stable atopic asthmatics who were on inhaled budesonide ( average 400 mcg/day) and montelukast or long-acting bronchodilator.</P>
<P>Inlcusion criteria: Clinical diagnosis of asthma of at least 6 months, resting FEV1 or at least 70% or more and reduction in FEV1 of 20% or more after exercise.</P>
<P>Exclusion criteria: recent upper respiratory tract infection (including sinusitis), previous intubation, or asthma hospitalization during 3 months before pre-study visit. Patients with significant co-morbidities and patients using beta-blocker, oral corticosteroids or immunotherapy were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>In random order: Budesonide turbuhaler 100mcg bid or placebo inhalers for 4 weeks.</P>
<P>Other treatment arms studied were: budesonide + formoterol ( 4.5 mcg bid) inhaler; Budesonide + montelukast ( 5 mg/day or 10mg /day depending on age ), montelukast ( 5mg/day or 10 mg/day depending on age ) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Maximal percentage fall in FEV1 after exercise was measured. The area under the curve (AUC) for the percentage fall in FEV1 from exercise over the 20 min period was calculated. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad score 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-28 15:23:24 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Thio-2001">
<CHAR_METHODS>
<P>RCT, Double-blind, crossover<BR/>Concomitant treatment: inhaled short-acting beta agonist as required ( stop12 hours before test)<BR/>Wash-out period of 7-14 days. <BR/>Exercise test: treadmill, 6 min, to achieve 90% maximum heart rate <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-28 15:23:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>N= 9. 6m,3f. Age: 9-16 year ( mean 11.2)<BR/>Inclusion criteria: fall in FEV1 &gt; 15% post-exercise, age between 8-16, ability to do lung function test, FEV1 &gt;70%, clinically stable for 3 weeks, no ICS, nasal or systemic steroids for 3 months, no cromoglycates in 2 weeks.<BR/>Exclusion criteria: theophylline, anticholinergics, and long-acting beta agonist.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: Fluticasone propionate inhaler 1 mg ( 250 mcg x 4) or placebo inhaler ( with MDI and spacer) . Exercise challenge test was performed 4 hours after the administration of inhalers.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 in the first 4 hours after administration of inhalers, maximum % fall in FEV1 from baseline FEV1 after exercise and AUC of time-response curve were measured. Protection index was calculated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vathenen-1991">
<CHAR_METHODS>
<P>RCT, double-blind, parallel study<BR/>Drop-out: 1 due to change in employment, 5 due to exacerbations of asthma<BR/>Concomitant treatment: short-acting beta agonist( stopped 8 hours before test)<BR/>Exercise: treadmill; 6 min; to achieve 90% maximum heart rate</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=40,28m,12f. Age: 18-45 (median 28). Inclusion criteria: Drop in FEV1 post exercise &gt;20%, asthma for 2 years or more, FEV1% predicted &gt; 50%, PD20 of 4micromol or less ,PV20 of 640L or less, not current smoker and had never smoked more than 10 cigarettes a day for 2 years, be having no treatment other than an inhaled beta2 agonist, stable asthma, no chest infection for at least 6 weeks before entry into the study. skin prick tests were performed in and 37 of the 40 subjects had a positive response( weal of more than 2 mm) to at least one allergen.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>In random order: Budesonide inhaler 800 mcg bid or placebo inhaler ( with MDI and spacer) for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 response to histamine, exercise and Eucapnic Voluntary Hyperventilation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-28 15:23:37 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Yazigi-1978">
<CHAR_METHODS MODIFIED="2008-07-28 15:23:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>RCT, double-blind, crossover<BR/>2 dropouts due to negative result on exercise testing with placebo.<BR/>Concomitant treatment: triamcinolone acetonide which was withheld for 12 hours before the exercise test.<BR/>Exercise test: treadmill ( 6 minutes, 3 mph, 15% grade)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-28 15:23:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>N=11. 6 m, 5 f. Age: 8-15 years. All had EIB as defined by fall in FEV1 of at least 15% after exercise in the last one week. All participants were already receiving triamcinolone acetonide aerosol ( 100mcg od - 300 mcg qid) for control of severe asthma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-28 15:23:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>In random order: A single dose of triamcinolone acetonide inhaler 300 mcg or placebo inhaler 15 minutes before exercise test. 24 hour washout period in-between.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, FEF25-75% vital capacity were measures immediately before exercise, and at 5 min interval for 15 min.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score =3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Beck_x002d_Ripp-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo and does not fulfill definition of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duong-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Freezer-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill criteria of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henriksen-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares ICS and placebo vs terbutaline and ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henriksen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hodges-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill criteria of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jonasson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill definition of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jonasson-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill definition of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konig-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill definition of EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Molema-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Molema-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morice-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-29 08:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nankani-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not EIB and not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nathan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patakas-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pedersen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Per-Venge-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pichaipat-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Subbarao-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vidal-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waalkens-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fulfill definition for EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not EIB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-14 06:27:20 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-14 06:27:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:22:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hartley-1977">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:22:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hofstra-2000">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:23:07 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jonasson-2000">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:23:20 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Petersen-2004">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-14 06:27:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:23:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Thio-2001">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:23:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Vathenen-1991">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-28 15:23:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Yazigi-1978">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-01-19 10:53:37 +0000" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2009-01-19 10:53:30 +0000" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>% fall index</NAME>
<CONT_OUTCOME CHI2="10.377603326983223" CI_END="-10.063159590087844" CI_START="-13.415399804282396" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.73927969718512" ESTIMABLE="YES" I2="80.72772742431079" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2009-01-19 01:58:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.005578722376974543" P_Q="1.0" P_Z="6.970411622019454E-43" Q="0.0" RANDOM="NO" SCALE="35.35" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="13.727277247912502">
<NAME>% fall index in FEV1 ( parallel studies, fixed)(&gt;/=4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.334303598929185" CI_START="-14.665696401070814" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="16.7" ORDER="74" SD_1="3.8" SD_2="9.1" SE="2.6356078182135843" STUDY_ID="STD-Jonasson-2000" TOTAL_1="14" TOTAL_2="14" WEIGHT="10.528160950348074"/>
<CONT_DATA CI_END="-12.61212346613287" CI_START="-18.187876533867136" EFFECT_SIZE="-15.400000000000002" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="22.1" ORDER="75" SD_1="4.26" SD_2="4.03" SE="1.422412123823472" STUDY_ID="STD-Vathenen-1991" TOTAL_1="18" TOTAL_2="16" WEIGHT="36.14624594887396"/>
<CONT_DATA CI_END="-7.404711457714555" CI_START="-11.99528854228545" EFFECT_SIZE="-9.700000000000003" ESTIMABLE="YES" MEAN_1="16.9" MEAN_2="26.6" MODIFIED="2008-10-30 00:47:17 +0000" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="4.47" SD_2="2.66" SE="1.1710871017990079" STUDY_ID="STD-Stelmach-2008" TOTAL_1="20" TOTAL_2="19" WEIGHT="53.32559310077796"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1774099749078775" CI_END="-1.8804727831116086" CI_START="-11.603455214071527" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.741963998591568" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.7584273290720378" P_Q="0.9711039773642933" P_Z="0.006565850726709256" Q="0.05864346768161255" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="68" UNITS="" WEIGHT="300.0" Z="2.7180973978167624">
<NAME>% fall index in FEV1 ( crossover studies)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9852117487852281" CI_START="-14.985211748785229" DF="0.0" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.08577025617212741" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.7181445305902543">
<NAME>% fall index in FEV1 (crossover studies)(&gt;/=4/52) (BDP100mcg )</NAME>
<CONT_DATA CI_END="0.9852117487852281" CI_START="-14.985211748785229" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="20.9" MEAN_2="27.9" ORDER="76" SD_1="13.1" SD_2="15.6" SE="4.074162490623072" STUDY_ID="STD-Petersen-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4278948267679574" CI_START="-14.627894826767953" DF="0.0" EFFECT_SIZE="-7.099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.06452177563648426" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="99.99999999999999" Z="1.8485572142629152">
<NAME>% fall index in FEV1 (crossover studies) (&gt;/=4/52)(BDP 50mcg )</NAME>
<CONT_DATA CI_END="0.4278948267679574" CI_START="-14.627894826767953" EFFECT_SIZE="-7.099999999999998" ESTIMABLE="YES" MEAN_1="20.8" MEAN_2="27.9" ORDER="77" SD_1="11.2" SD_2="15.6" SE="3.840833242930497" STUDY_ID="STD-Petersen-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.118766507226265" CI_END="4.963070185600853" CI_START="-16.13924459144093" DF="1.0" EFFECT_SIZE="-5.588087202920039" ESTIMABLE="YES" I2="10.615844008480403" ID="CMP-001.02.03" NO="3" P_CHI2="0.29018424841853596" P_Z="0.29925470215030825" STUDIES="2" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="1.0380330097348505">
<NAME>% fall index in FEV1 ( crossover studies) ( single dose )</NAME>
<CONT_DATA CI_END="3.301264195509475" CI_START="-22.301264195509475" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="19.2" ORDER="78" SD_1="9.2" SD_2="17.3" SE="6.531377258196688" STUDY_ID="STD-Thio-2001" TOTAL_1="9" TOTAL_2="9" WEIGHT="67.93514100754129"/>
<CONT_DATA CI_END="21.33311370278381" CI_START="-15.93311370278381" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="28.3" ORDER="79" SD_1="2.62" SD_2="28.4" SE="9.506865355567465" STUDY_ID="STD-Yazigi-1978" TOTAL_1="9" TOTAL_2="9" WEIGHT="32.06485899245871"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.7404982073301323" CI_START="-20.259501792669866" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.010077506697016925" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="2.57315842335602">
<NAME>% fall index in PEF ( crossover studies)( &gt;/= 4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.7404982073301323" CI_START="-20.259501792669866" EFFECT_SIZE="-11.5" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="23.8" ORDER="80" SD_1="11.2" SD_2="15.3" SE="4.469215690575796" STUDY_ID="STD-Hartley-1977" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.745658823129252" CI_END="-2.992169559658693" CI_START="-10.568884509887118" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-6.780527034772906" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-01-19 10:53:22 +0000" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.6268310638260315" P_Q="0.9878556494179174" P_Z="4.514752694524152E-4" Q="0.02443739333498751" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4" TOTAL_2="4" WEIGHT="300.0" Z="3.5080081200506044">
<NAME>% fall index in FEV1 (crossover studies, GIV, fixed)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.458119448965612E-32" CI_END="-0.1499258740325109" CI_START="-13.850074125967492" DF="0.0" EFFECT_SIZE="-7.000000000000001" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.0" P_Z="0.045192185461299744" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.002861230329042">
<NAME>% fall index FEV1 ( crossover studies, GIV, fixed)( &gt;/=4/52)( BDP 50 mcg)</NAME>
<IV_DATA CI_END="-0.14992587403251" CI_START="-13.85007412596749" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" SE="3.495" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.7212214297942645" CI_END="6.480938930737929" CI_START="-16.554014668442846" DF="1.0" EFFECT_SIZE="-5.0365378688524585" ESTIMABLE="YES" I2="41.901722655200224" ID="CMP-001.04.02" LOG_CI_END="0.8116379291574423" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.18953599362827023" P_Z="0.3913990598073457" STUDIES="2" TAU2="31.183262000000013" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="0.8570829359147492">
<NAME>% fall index FEV1 (crossover studies, GIV, fixed) ( single dose)</NAME>
<IV_DATA CI_END="-0.04513373857877845" CI_START="-18.954866261421223" EFFECT_SIZE="-9.5" ESTIMABLE="YES" ESTIMATE="-9.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" SE="4.824" STUDY_ID="STD-Thio-2001" TOTAL_1="1" TOTAL_2="1" WEIGHT="73.08888566015318"/>
<IV_DATA CI_END="18.281713677093432" CI_START="-12.881713677093433" EFFECT_SIZE="2.7" ESTIMABLE="YES" ESTIMATE="2.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" SE="7.95" STUDY_ID="STD-Yazigi-1978" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.911114339846822"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-1.400341059380608" CI_START="-12.399658940619393" DF="0.0" EFFECT_SIZE="-6.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-01-19 10:53:22 +0000" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="1.0" P_Z="0.013931825597270912" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.459016393442623">
<NAME>% fall index FEV1 (crossover studies,GIV, fixed) (&gt;/=4/52)( BDP 100mcg)</NAME>
<IV_DATA CI_END="-1.400341059380608" CI_START="-12.399658940619393" EFFECT_SIZE="-6.9" ESTIMABLE="YES" ESTIMATE="-6.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84" SE="2.806" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-6.306095440968856" CI_START="-16.693904559031143" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-11.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.4272759488179739E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.339622641509434">
<NAME>% fall index PEF (crossover studies, GIV, fixed)( &gt;/= 4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_DATA CI_END="-6.306095440968856" CI_START="-16.693904559031143" EFFECT_SIZE="-11.5" ESTIMABLE="YES" ESTIMATE="-11.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85" SE="2.65" STUDY_ID="STD-Hartley-1977" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="10.377603326983225" CI_END="-7.509333029724928" CI_START="-15.89528888216779" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.70231095594636" ESTIMABLE="YES" I2="80.72772742431079" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-10-30 00:47:41 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.005578722376974432" P_Q="1.0" P_Z="4.497215350436158E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="10.675754484954387" TOTALS="YES" TOTAL_1="52" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="5.470123719495132">
<NAME>% fall index FEV1 ( parallel studies , random)(&gt;/=4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.334303598929185" CI_START="-14.665696401070814" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="16.7" ORDER="86" SD_1="3.8" SD_2="9.1" SE="2.6356078182135843" STUDY_ID="STD-Jonasson-2000" TOTAL_1="14" TOTAL_2="14" WEIGHT="25.971035256961937"/>
<CONT_DATA CI_END="-7.404711457714555" CI_START="-11.99528854228545" EFFECT_SIZE="-9.700000000000003" ESTIMABLE="YES" MEAN_1="16.9" MEAN_2="26.6" MODIFIED="2008-10-30 00:47:41 +0000" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="4.47" SD_2="2.66" SE="1.1710871017990079" STUDY_ID="STD-Stelmach-2008" TOTAL_1="20" TOTAL_2="19" WEIGHT="37.98943796303311"/>
<CONT_DATA CI_END="-12.61212346613287" CI_START="-18.187876533867136" EFFECT_SIZE="-15.400000000000002" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="22.1" ORDER="87" SD_1="4.26" SD_2="4.03" SE="1.422412123823472" STUDY_ID="STD-Vathenen-1991" TOTAL_1="18" TOTAL_2="16" WEIGHT="36.03952678000495"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.745658823129252" CI_END="-2.9921695596586937" CI_START="-10.56888450988712" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-6.7805270347729065" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-01-19 10:53:30 +0000" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="0.6268310638260315" P_Q="0.9878556494179174" P_Z="4.5147526945241444E-4" Q="0.02443739333498751" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4" TOTAL_2="4" WEIGHT="300.0" Z="3.508008120050605">
<NAME>% fall index FEV1 (crossover, GIV, random)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.458119448965612E-32" CI_END="-0.1499258740325109" CI_START="-13.850074125967492" DF="0.0" EFFECT_SIZE="-7.000000000000001" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.07.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.0" P_Z="0.045192185461299744" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.002861230329042">
<NAME>% fall index FEV1 (crossover, GIV, random) ( BDP50 mcg)(&gt;/=4/52)</NAME>
<IV_DATA CI_END="-0.14992587403251" CI_START="-13.85007412596749" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="88" SE="3.495" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-1.400341059380608" CI_START="-12.399658940619393" DF="0.0" EFFECT_SIZE="-6.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.013931825597270912" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.459016393442623">
<NAME>% fall index FEV1 ( crossover, GIV, random) (BDP 100mcg)(&gt;/=4/52)</NAME>
<IV_DATA CI_END="-1.400341059380608" CI_START="-12.399658940619393" EFFECT_SIZE="-6.9" ESTIMABLE="YES" ESTIMATE="-6.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="89" SE="2.806" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.7212214297942645" CI_END="6.480938930737929" CI_START="-16.554014668442846" DF="1.0" EFFECT_SIZE="-5.0365378688524585" ESTIMABLE="YES" I2="41.901722655200224" ID="CMP-001.07.03" LOG_CI_END="0.8116379291574423" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-01-19 10:53:30 +0000" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.18953599362827023" P_Z="0.3913990598073457" STUDIES="2" TAU2="31.183262000000013" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="0.8570829359147492">
<NAME>% fall FEV1( crossover, GIV, random) (single dose)</NAME>
<IV_DATA CI_END="-0.04513373857877845" CI_START="-18.954866261421223" EFFECT_SIZE="-9.5" ESTIMABLE="YES" ESTIMATE="-9.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" SE="4.824" STUDY_ID="STD-Thio-2001" TOTAL_1="1" TOTAL_2="1" WEIGHT="73.08888566015318"/>
<IV_DATA CI_END="18.281713677093432" CI_START="-12.881713677093433" EFFECT_SIZE="2.7" ESTIMABLE="YES" ESTIMATE="2.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" SE="7.95" STUDY_ID="STD-Yazigi-1978" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.911114339846822"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-6.306095440968856" CI_START="-16.693904559031143" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-11.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="1.4272759488179739E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="4.339622641509434">
<NAME>% fall index PEF ( crossover, GIV, random)(&gt;/=4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>%</EFFECT_MEASURE>
<IV_DATA CI_END="-6.306095440968856" CI_START="-16.693904559031143" EFFECT_SIZE="-11.5" ESTIMABLE="YES" ESTIMATE="-11.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" SE="2.65" STUDY_ID="STD-Hartley-1977" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="27.649429631420922" CI_START="-12.649429631420922" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.4656739942936966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="99.99999999999999" Z="0.7295357810589199">
<NAME>% fall index PEF (crossover studies)(single dose)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="27.649429631420926" CI_START="-12.649429631420926" EFFECT_SIZE="7.5" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="22.5" ORDER="93" SD_1="22.4" SD_2="21.2" SE="10.280510147307325" STUDY_ID="STD-Yazigi-1978" TOTAL_1="9" TOTAL_2="9" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-01-19 01:56:50 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>% fall index in FEV1 ( parallel studies, fixed)(&gt;/=4/52)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-01-19 10:53:35 +0000" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Adverse outcomes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.001708006335201" CI_START="0.27866360428784476" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3968253968253967" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8452039953348187" LOG_CI_START="-0.554919749941645" LOG_EFFECT_SIZE="0.14514212269658688" METHOD="MH" MODIFIED="2009-01-19 10:53:35 +0000" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6844821043145878" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4063545584234524">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>ICS (Bud 100mcg)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.001708006335201" CI_START="0.27866360428784476" EFFECT_SIZE="1.3968253968253967" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8452039953348187" LOG_CI_START="-0.554919749941645" LOG_EFFECT_SIZE="0.14514212269658688" ORDER="94" O_E="0.0" SE="0.8224396186997112" STUDY_ID="STD-Petersen-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.6764069264069263" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.159193437595083" CI_START="0.029553175319944055" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.49957621859528833" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090621" METHOD="MH" MODIFIED="2009-01-19 10:53:35 +0000" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.31983644275271494" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.9947940729134134">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>ICS (Bud 50 mcg)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.159193437595083" CI_START="0.029553175319944055" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49957621859528833" LOG_CI_START="-1.5293958498134126" LOG_EFFECT_SIZE="-0.5149098156090621" ORDER="95" O_E="0.0" SE="1.1918282365569903" STUDY_ID="STD-Petersen-2004" TOTAL_1="25" TOTAL_2="25" VAR="1.4204545454545454" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-01-19 10:53:37 +0000" MODIFIED_BY="Toby J Lasserson" NO="3">
<NAME>Measures of airway inflammation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.22543738388546128" CI_START="-0.06543738388546125" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2009-01-19 10:53:37 +0000" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.28098584923131" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0781073928467348">
<NAME>Dose of histamine causing 20% fall in FEV1 (PD20)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.22543738388546128" CI_START="-0.06543738388546125" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.45" ORDER="96" SD_1="0.3" SD_2="0.09" SE="0.07420411039827915" STUDY_ID="STD-Vathenen-1991" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.07173601147776197" CI_END="-5.004364504341014" CI_START="-5.781288293363435" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="-5.3928263988522245" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-01-19 10:53:37 +0000" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.7888257246835151" P_Q="0.7888257246835151" P_Z="0.0" Q="0.07173601147776197" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.00000000000001" Z="27.20922094540777">
<NAME>Exhaled Nitric Oxide ( crossover)</NAME>
<GROUP_LABEL_1>ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-2.0992533028807197" CI_START="-7.90074669711928" DF="0.0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="7.291467762529553E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="1.7934002869440464" Z="3.3783783783783785">
<NAME>Exhaled Nitric Oxide ( crossover) BDP 50mcg vs placebo</NAME>
<IV_DATA CI_END="-2.0992533028807197" CI_START="-7.90074669711928" EFFECT_SIZE="-5.0" ESTIMABLE="YES" ESTIMATE="-5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="97" SE="1.48" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="1.7934002869440464"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-5.0080072030919895" CI_START="-5.791992796908011" DF="0.0" EFFECT_SIZE="-5.4" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="98.20659971305597" Z="27.0">
<NAME>Exhaled Nitric Oxide ( crossover) BDP 100mcg vs placebo</NAME>
<IV_DATA CI_END="-5.0080072030919895" CI_START="-5.791992796908011" EFFECT_SIZE="-5.4" ESTIMABLE="YES" ESTIMATE="-5.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="98" SE="0.2" STUDY_ID="STD-Petersen-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="98.20659971305597"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-01-19 01:58:36 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-01-19 01:58:36 +0000" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 % fall index, outcome: 1.1 % fall index in FEV1 ( parallel studies, fixed)(&gt;/=4/52).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAACgCAMAAABUggjsAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>